PRECIGEN, INC. Repayment of Notes Receivable from Related Parties
PRECIGEN, INC. (PGEN) reported Repayment of Notes Receivable from Related Parties of $0 for the 9-month period ending 2014-09-30, per its 10-Q filed 2014-11-13.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:RepaymentOfNotesReceivableFromRelatedParties · last filed 2014-11-13
- PRECIGEN, INC. repayment of notes receivable from related parties for the quarter ending 2013-12-31 was $0.00.
- PRECIGEN, INC. repayment of notes receivable from related parties for the quarter ending 2013-09-30 was $0.00.
- PRECIGEN, INC. repayment of notes receivable from related parties for the quarter ending 2013-06-30 was $0.00.
- PRECIGEN, INC. repayment of notes receivable from related parties for the quarter ending 2013-03-31 was $500.00K.
- PRECIGEN, INC. repayment of notes receivable from related parties for fiscal 2013 was $500.00K, a 1370.59% increase from fiscal 2012.
- PRECIGEN, INC. repayment of notes receivable from related parties for fiscal 2012 was $34.00K, a 88.67% decline from fiscal 2011.
- PRECIGEN, INC. repayment of notes receivable from related parties for fiscal 2011 was $300.00K.
| Period end | Repayment of Notes Receivable from Related Parties 3 month | Repayment of Notes Receivable from Related Parties 6 month | Repayment of Notes Receivable from Related Parties 9 month | Repayment of Notes Receivable from Related Parties 12 month |
|---|---|---|---|---|
| 2014-09-30 | $0.00 10-Q · filed 2014-11-13 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-31 | $0.00 derived: sum of 2 quarters · filed 2014-11-13 | $0.00 derived: sum of 3 quarters · filed 2014-11-13 | $500.00K 10-K · filed 2014-03-31 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $0.00 derived: sum of 2 quarters · filed 2014-11-13 | $500.00K 10-Q · filed 2014-11-13 | $500.00K derived: sum of 4 quarters · filed 2014-11-13 |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $500.00K 10-Q · filed 2014-08-14 | $500.00K derived: sum of 3 quarters · filed 2014-08-14 | $500.00K derived: sum of 4 quarters · filed 2014-08-14 |
| 2013-03-31 | $500.00K 10-Q · filed 2014-05-09 | $500.00K derived: sum of 2 quarters · filed 2014-05-09 | $500.00K derived: sum of 3 quarters · filed 2014-05-09 | |
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-31 | $0.00 derived: sum of 2 quarters · filed 2014-03-31 | $34.00K 10-K · filed 2014-03-31 | |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2013-11-07 | $34.00K 10-Q · filed 2013-11-07 | ||
| 2012-06-30 | $34.00K 10-Q/A · filed 2013-10-21 | |||
| 2011-12-31 | $300.00K 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |